Skip to content

These Biotech Companies Await FDA Decisions In October

There’s perhaps no greater catalyst for shares of a biotech company than FDA approval of one of its product candidates. Conversely, an unfavorable ruling by the FDA can send shares of a biotech firm plummeting. With the FDA having approved 40 novel drugs so far this year (compared to 27 by this same time last year), today’s article takes a look at biotech companies that are expected to receive FDA rulings in October. For more, CLICK HERE.